- Home
- YMAB vs JCE Comparison
YMAB vs JCE Comparison
Compare YMAB & JCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YMAB
- JCE
- Stock Information
- Founded
- YMAB 2015
- JCE 2007
- Country
- YMAB United States
- JCE United States
- Employees
- YMAB N/A
- JCE N/A
- Industry
- YMAB Biotechnology: Pharmaceutical Preparations
- JCE Trusts Except Educational Religious and Charitable
- Sector
- YMAB Health Care
- JCE Finance
- Exchange
- YMAB Nasdaq
- JCE Nasdaq
- Market Cap
- YMAB 218.4M
- JCE 237.9M
- IPO Year
- YMAB 2018
- JCE N/A
- Fundamental
- Price
- YMAB $4.69
- JCE N/A
- Analyst Decision
- YMAB Buy
- JCE
- Analyst Count
- YMAB 11
- JCE 0
- Target Price
- YMAB $18.73
- JCE N/A
- AVG Volume (30 Days)
- YMAB 318.1K
- JCE 49.7K
- Earning Date
- YMAB 05-06-2025
- JCE 01-01-0001
- Dividend Yield
- YMAB N/A
- JCE 9.26%
- EPS Growth
- YMAB N/A
- JCE N/A
- EPS
- YMAB N/A
- JCE N/A
- Revenue
- YMAB $87,685,000.00
- JCE N/A
- Revenue This Year
- YMAB N/A
- JCE N/A
- Revenue Next Year
- YMAB $21.10
- JCE N/A
- P/E Ratio
- YMAB N/A
- JCE N/A
- Revenue Growth
- YMAB 3.38
- JCE N/A
- 52 Week Low
- YMAB $3.86
- JCE $11.64
- 52 Week High
- YMAB $17.78
- JCE $14.28
- Technical
- Relative Strength Index (RSI)
- YMAB 47.75
- JCE 40.24
- Support Level
- YMAB $4.46
- JCE $13.30
- Resistance Level
- YMAB $5.44
- JCE $14.03
- Average True Range (ATR)
- YMAB 0.45
- JCE 0.59
- MACD
- YMAB 0.07
- JCE 0.02
- Stochastic Oscillator
- YMAB 52.53
- JCE 50.00
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.